November 17, 2020 -- Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.
After the deal was initially signed in May, Samsung delivered an initial supply of active pharmaceutical ingredients (APIs) meeting good manufacturing practice (GMP) and regulatory expectations within five months, the firm said. What's more, technology transfer was completed in less than three months, according to Samsung.
The agreement supplements Lilly's internal manufacturing capacity.